Kyndryl, Hims & Hers, Novo Nordisk, Kroger, Nvidia, Monday.com, and More Movers - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Kroger, Nvidia, Monday.com, and MoreBy [Mac ...

Group 1 - Novo Nordisk is suing Hims & Hers over the sale of copycat versions of its Wegovy obesity treatment, claiming it deceives patients and risks their health [3] - Hims & Hers announced it would withdraw its copycat weight-loss pill from the market after legal threats from Novo Nordisk, which sells its pills for approximately $149 [3] - Shares of Hims & Hers fell over 20% in premarket trading, while Novo Nordisk's shares rose about 5.5% [4] Group 2 - Meta is facing two significant trials this week that could impact the company and the social media industry [6] - In New Mexico, Meta is accused of failing to protect child users from online predators and facilitating access to exploitative materials [7] - A separate trial in Los Angeles involves allegations that Meta and other platforms did not inform users about potential mental health risks associated with their apps [7] Group 3 - Gen Z is showing a strong interest in the aesthetic of 2016, with increased searches and playlists from that year [8] - This trend is attributed to economic unease, leading consumers to revert to familiar styles from a perceived stable era [9] - Brands like Abercrombie & Fitch, Victoria's Secret, and Urban Outfitters are expected to benefit from this nostalgia-driven consumer behavior [9]

>> IT’S 5:00 AM IN NEW YORK CITY, GOOD MORNING, I'M LIZZY BURDEN IN FOR VONNIE QUINN. LET'S GET YOU SET UP FOR THE DAY. THE DOLLAR SLIPS AND YIELDS ARRIVED -- RISE ACROSS THE CURVE.THE YEN IS ALSO ON THE MOVE STRENGTHENING AGAINST THE DOLLAR FOLLOWING THE PRIME MINISTER'S LANDSLIDE VICTORY. ALL OF THAT IN A BUSY WEEK FOR DATA WITH THE LATEST JOBS REPORT AND FRENCH INFLATION PRINT. WE SAW THE GAINS ON WALL STREET ON FRIDAY CARRYING INTO THE NEW WEEK.SEEING A FAIRLY RISK ON MOVE IN THE ASIAN AND EUROPEAN SESS ...

Novo Nordisk says it’s suing Hims & Hers Health for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill https://t.co/zlpjbcIeyF ...

Group 1 - Hong Kong media tycoon Jimmy Lie sentenced to 20 years in prison under a national security law, impacting the political landscape of the city [1] - President Trump endorses NextStar's proposed $6.2 billion acquisition of Tegna, with Tegna shares rising by approximately 4.8% [2] - Novo Nordisk shares increase by 6.7% after Hims and Hers announces it will withdraw its copycat weight loss pill from the market, while Hims and Hers shares drop by about 15% [3] Group 2 - Fintech company Block may lay off up to 10% of its workforce, indicating potential restructuring [4] - Kroger plans to hire former Walmart US CEO Greg Forand as its next chief, following a year-long search for a permanent leader after the ousting of Rodney McMullen [4] - Kroger shares rise by approximately 5.25% following the news of the leadership change [4]

Company Movements - Hims & Hers Health (HIMS) is experiencing a 15% decline in premarket trading after announcing it will stop offering a compounded version of Novo Nordisk's Wegovy pill due to pressure from Novo and FDA scrutiny [3][4] - Novo Nordisk shares rose by 7% in premarket trading following HIMS's announcement [4] - Samsung Electronics (SSNLF) shares increased by 6.4% after reports of imminent mass production of HBM4 memory chips, which are essential for AI infrastructure [4][5] Industry Developments - Luckin Coffee (LKNCY) is targeting Starbucks (SBUX) premium market with the opening of its first flagship store in Shenzhen, marking a shift from its budget store model [5][6] - The new flagship store features higher-priced offerings compared to Luckin's typical $1-$2 drinks, and it is the first to use high-end semi-automatic coffee machines [7]

Group 1: Hims & Hers Health (HIMS) - Hims & Hers Health announced it will stop offering a compounded version of Novo Nordisk's Wegovy pill due to pressure from Novo and increased FDA scrutiny [3][4] - Following this announcement, HIMS shares fell by 15% in premarket trading [2] Group 2: Samsung Electronics (SSNLF) - Samsung Electronics' shares rose by 6.4% after reports of imminent mass production of HBM4 memory chips, which are essential for AI infrastructure [4] - The company plans to ship these semiconductors to Nvidia as early as the third week of February [5] Group 3: Luckin Coffee (LKNCY) - Luckin Coffee inaugurated its 30,000th store, marking a shift towards targeting Starbucks' premium market with its first flagship store in Shenzhen [5][6] - The flagship store features higher-priced offerings compared to typical Luckin products, with a focus on pour-over and cold brew coffee drinks [7] - This store also represents Luckin's first use of high-end semi-automatic coffee machines [7]

Core Insights - Novo Nordisk's stock price surged due to the strong performance of its weight-loss drugs Ozempic and Wegovy, with shares increasing by 8.26% in Copenhagen and 7.05% in New York pre-market [1] - The rally followed Hims & Hers Health Inc's decision to withdraw its Wegovy copycat drug amid legal threats from Novo Nordisk, which contributed to a significant drop in HIMS stock by 15.38% [2][1] - Novo Nordisk's total revenue for 2025 is projected at approximately $46.8 billion, with Ozempic, Wegovy, and Rybelsus contributing $35.6 billion, highlighting the critical role of these drugs in the company's financial health [5][4] Company Performance - Ozempic is primarily a diabetes medication but is also used for weight loss due to its side effects, while Wegovy is specifically designed for weight management [6][5] - Despite the recent stock rally, Wall Street analysts express uncertainty regarding Novo Nordisk's outlook for 2026, with an average 12-month price target set at $56.83, which is above the latest closing price but below the current 2026 high of about $63 [8][7][10] - The recent withdrawal of Hims & Hers has not yet been factored into institutional forecasts, indicating potential for significant changes in market expectations [10]

Good morning. It is Monday, the ninth. On today's agenda is historic triumph.China warns on treasurys and Starmer on the brink. Tom there's some really interesting moves developing in the bull market right now. Let's talk about what is happening.As you say, tucker ichi wins big. The japanese ten year goes higher, 30 year goes higher. Is that the repatriation trade beginning.Does it give legs to the repatriation trade back into Japan out of treasuries. The event, as you say, got the Chinese talking to privat ...

Company Developments - Kroger Co. is set to appoint Greg Foran, a former Walmart executive, as its new CEO, following a year-long search for leadership. This move aims to enhance Kroger's strategy in a competitive retail environment, particularly focusing on fresh food and store efficiency. Kroger shares rose nearly 3% in premarket trading after the news [3][7] - Eli Lilly's shares increased by 2.2% in premarket trading after Hims & Hers Health Inc. withdrew its weight-loss pill, reducing competition in the weight-loss drug market. This withdrawal follows a terminated partnership with Novo Nordisk due to concerns over marketing practices, potentially benefiting Eli Lilly's weight-loss treatments like Zepbound [4][7] Market Sentiment - The Eurozone's investor sentiment improved significantly, with the Sentix Investor Confidence index rising to 4.2 in February, surpassing the estimated 0.0 and increasing from -1.8 the previous month. This indicates growing optimism among investors regarding the Eurozone's economic outlook [5][7] Political and Economic Context - The British Pound and UK Gilts are under pressure due to a leadership crisis involving Prime Minister Keir Starmer, which has increased political risk premiums in the currency and bond markets. The resignation of Starmer's adviser amid controversy has heightened uncertainty, potentially affecting public debt sustainability [6][8] - Fitch Ratings upgraded China Vanke's Long-Term Foreign-Currency Issuer Default Rating to 'CC', indicating a very high level of default risk. Despite the upgrade, the company faces significant financial challenges, including a profit warning projecting a net loss for 2025 [9]